Weight Loss Injections and Crohn's Disease: What You Need to Consider

Do GLP-1 medicines affect the gut in ways that matter for Crohn's?

It is a fair question to start with, and one our prescribers hear fairly often. Tirzepatide (Mounjaro) and semaglutide (Wegovy) both slow gastric emptying, the rate at which the stomach empties its contents into the small intestine. This is part of how they reduce appetite. In a gut that is already inflamed or structurally altered by Crohn's disease, slower transit can amplify existing symptoms or make it harder to tell a medication side effect from a flare.

The most common side effects of both medicines are gastrointestinal: nausea, loose stools, vomiting, stomach discomfort. For most people these settle within the first few weeks of each dose. For someone managing active Crohn's, the same symptoms are already part of daily life. That overlap matters clinically because it can delay recognising a genuine flare, complicate fluid balance, and make dose titration harder to manage safely.

There is also a separate concern around absorption. Crohn's can reduce absorption of nutrients and, in some cases, of oral medications, relevant if someone is also taking the oral semaglutide tablet (Wegovy tablets), which requires an intact stomach lining and specific fasting conditions to absorb reliably. You can read a broader overview of how these treatments work on our weight loss injections page, which explains the mechanism behind both semaglutide and tirzepatide in plain terms.

None of this means the medicines are ruled out. It means the prescriber needs to understand your Crohn's in some detail before proceeding, and that is exactly what the clinical assessment process is designed to do.

Is Crohn's disease a contraindication to Mounjaro or Wegovy?

Neither the Mounjaro nor the Wegovy Summary of Product Characteristics (SmPC) lists Crohn's disease as an absolute contraindication. The contraindications that are listed include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and a history of serious hypersensitivity to the active substance. Severe gastroparesis (a condition of very slow stomach emptying) is listed as a reason to avoid tirzepatide specifically, which is worth noting for people whose Crohn's has affected stomach motility.

What the SmPC and clinical guidance do flag is the need for caution in anyone with a history of inflammatory bowel conditions, given the GI mechanism of action and the overlapping symptom profile. The January 2026 MHRA Drug Safety Update on GLP-1 medicines also reinforced the need for awareness of acute pancreatitis as an infrequent but serious risk: severe, persistent stomach pain that spreads to the back warrants urgent medical attention and should not be attributed to Crohn's without proper investigation.

In practice, prescribers consider disease activity at the time of assessment, surgical history (bowel resections in particular affect how the gut handles these medicines), current immunosuppressant or biologic therapy, and nutritional status. Someone in sustained remission with stable disease looks very different from someone in an active flare, and a clinical assessment can draw that distinction where a tick-box form cannot. More on the detailed considerations specific to Crohn's is available at can you take weight loss injections with Crohn's disease.

What about interactions with Crohn's medications?

This is where individual circumstances really diverge. Many people with Crohn's take medicines that have their own metabolic or gastrointestinal profiles: immunosuppressants such as azathioprine or methotrexate, biologics such as adalimumab or vedolizumab, corticosteroids during flares, or aminosalicylates. If you are living with both conditions and want a thorough picture of what the evidence currently shows, our page on weight loss injections and Crohn's disease brings together the key clinical considerations in one place.

Steroids, used in Crohn's flare management, can raise blood glucose and counteract some of the metabolic benefits of weight-loss medicines. If you are also managing blood sugar, that interplay needs a prescriber's eye. Methotrexate has its own GI side effects; combining it with a medicine that also causes nausea increases the chance of tolerability problems.

Tirzepatide is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK, and it is a relatively newer medicine, the MHRA's Black Triangle (▼) status for both Mounjaro and Wegovy reflects ongoing post-market surveillance. Your prescriber should have visibility of your full medication list before any prescription is issued. If you want to explore what private treatment looks like in terms of cost and what is included, our weight loss treatment overview sets that out clearly.

How should someone with Crohn's approach the conversation with a prescriber?

The most useful thing you can do before a consultation is be specific: current disease activity (in remission, or not), when you last had a flare, what surgery you have had on your bowel if any, your current medication list, and your most recent blood results if available. A prescriber cannot make a good call without that information, and trying to get one without it is a risk you do not need to take.

If you have been considering these treatments and feel a bit stuck (not sure whether your history rules you out or not) that is a very normal place to be. The licensing criteria for these medicines are set at a population level, and your situation is specific. People sometimes also ask whether other conditions or circumstances affect eligibility, and our guidance on MS and weight loss injections is a useful example of how we think through complex health histories alongside these treatments. Some people in this situation also find it helpful to read about NAD injections and weight loss, particularly where they are curious about supportive approaches that sit alongside or separately from GLP-1 therapy. A proper clinical review is the only way to get an answer that actually applies to you rather than a generalisation.

You can read about how our clinical team approaches complex situations on the clinical team profile. Reporting any side effects you experience once on treatment to the MHRA via the Yellow Card scheme is also straightforward and genuinely useful for ongoing post-market safety monitoring of these medicines. If you have questions before starting, our FAQs cover a range of situations, or you can get in touch directly. When you are ready to go further, speaking to our prescribers is the right next step, start your free consultation here.